Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma: New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer ...

When a tumor develops, it creates a structure around itself called the tumor stroma, within which blood and lymphatic vessels ...

Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application ...

NEW YORK, NY, USA I 12, 2025 I Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental ...

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) and its oncology-focused subsidiary, Citius ...

The next donor recruitment drives for the Marshall's Match campaign are being held this weekend - with one taking place at AFC Telford's match on Saturday.

Cytokines and their receptors play a major role in the pathogenesis and pathophysiology of human lymphomas. IL-13 is a growth factor for tumor cells in mycosis fungoides and Hodgkin lymphoma and is ...

University Centre of General Dermatology and Oncodermatology, Faculty of Medicine, Wroclaw Medical University, Wroclaw, Poland Faculty of Medicine, Wroclaw University of Science and Technology, ...

The cause of mycosis fungoides is unknown and ... no skin tumors, no lymph nodes or visceral involvement IB: >10% body surface area involved, otherwise same as IB IIA: skin involvement similar ...

This process usually takes a few weeks, known as the bridging period, during which additional chemotherapy or radiotherapy is often given to keep the lymphoma stable. Once the CAR T-cell product is ...